ZNF281 Emerges as a Novel Driver and Therapeutic Target in Advanced Prostate Cancer

ZNF281 is a Krüppel-type zinc-finger transcription factor previously implicated in cancer stemness, but its role in prostate cancer has remained largely unexplored. In a new study, researchers evaluated ZNF281 expression across human prostate cancer samples, including primary tumors, metastatic lymph nodes, and normal prostate tissue. The findings revealed significantly higher expression of ZNF281 in metastatic lesions compared to both primary tumors and normal tissue, suggesting a strong association with disease progression and metastatic potential.

Mechanistically, the study provides important insight into how ZNF281 may drive tumor biology. The protein was shown to directly interact with the androgen receptor, acting as a transcriptional co-activator that enhances AR-driven gene expression. This is particularly relevant given that AR signaling remains a central driver of prostate cancer growth even in advanced and castration-resistant disease. At the same time, ZNF281 was found to promote the expression of EMT-related proteins, including SNAIL, linking it to cellular plasticity, invasion, and metastatic dissemination. This dual role places ZNF281 at a critical intersection between proliferative signaling and metastatic programming.

To explore its therapeutic potential, the researchers tested a rhodanine-based small-molecule inhibitor targeting ZNF281 in multiple experimental models. In an orthotopic xenograft mouse model of human prostate cancer, oral administration of the inhibitor significantly reduced tumor growth and suppressed metastasis to distant organs such as the liver and lungs. Notably, genetic knockout of ZNF281 produced similar effects, reinforcing the conclusion that ZNF281 is a functional driver of disease progression rather than a passive biomarker.

The study further evaluated efficacy in patient-derived organoids, which better capture patient-specific tumor biology. In this model, ZNF281 inhibition not only reduced tumor growth but also demonstrated superior activity compared to enzalutamide, one of the current standard therapies targeting the androgen receptor pathway. This finding suggests that targeting ZNF281 could offer an alternative or complementary approach, particularly in settings where resistance to conventional AR-directed therapies emerges.

Although these results are promising, they remain preclinical and several limitations should be considered. The number of human samples analyzed was relatively small, and the inhibitor used is still an early-stage compound requiring further optimization for specificity, safety, and pharmacokinetic properties. In addition, the study does not yet address how ZNF281 targeting performs in distinct clinical contexts such as castration-resistant prostate cancer or tumors driven by AR splice variants.

Source.